Based on long-term data from a late-stage trial including 30,000 participants, Moderna’s COVID-19 vaccine candidate has shown results of a 95% efficacy rate in fighting the virus. Moderna is planning to file for Emergency Use Authorization (EUA) in the coming weeks, ad by partnering with the United States Government’s Operation Warp Speed Program, they plan to release 20 million doses this year alone pending U.S. Food and Drug Administration (FDA) authorization. The 95 cases of COVID-19 within the 30,000 participants were in people with designated high-risk criteria, and the side effects were mild to moderate including achiness proceeding the second round of the vaccine.
Read more here.
More on: News Regulatory